Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Patent: 8,425,906

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,425,906
Title:Method to inhibit cancer targeting CD24
Abstract: The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24.
Inventor(s): Shin; Young Kee (Seoul, KR), Choi; Yoon-La (Seoul, KR), Park; Young Woo (Daejeon-si, KR), Lee; Seung Hyun (Anyang-si, KR), Song; Kyoung (Incheon, KR)
Assignee: SNU R&DB Foundation (Seoul, KR)
Application Number:12/307,108
Patent Claims:see list of patent claims

Details for Patent 8,425,906

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Try it Free 2026-06-30
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 2002-02-19 ⤷  Try it Free 2026-06-30
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 1997-12-10 ⤷  Try it Free 2026-06-30
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 1998-08-24 ⤷  Try it Free 2026-06-30
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Try it Free 2026-06-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.